Amarin Corp Plc (AMRN)

[Biobillionair]

Unless AZN would like to launch AMR102 late next year and cut Actavis and Egis's generic launch in 2016.

Or perhaps Pfizer would like to be first in the combo market?

Or maybe TEVA would like to sign Royality aggrement for Vascepa/lipitor and Amarin launches this first?

Or perhaps Mylan Pharmaceuticals signs a Royality agreement tomorrow to launch the Vascepa/Crestor combo ASAP, since it's generic already in Canada.

Or Merck, decides they don't want any of the above and they buy Amarin over the weekend.

Or GSK, knowing that the lose the Lovaza market after the Anchor indication is approved, decides to step in before Merck.

But I'm pretty sure Pfizer has been working the math out and is likely to make a play before any of the above transpires....?

At this point if BP doesn't want Amarin to start signing AMR102 Royality agreements they better pull the trigger, soon.

I would like Amarin to do none of the above and develop the EPA market for all inflammatory diseases through biologics, perhaps something Biogen Idec would be interested in. Biogen is extremely successful in the MS market and Resolvins have a huge role to play;)---just dropped them an email on some cool NIH studies.

Designing a drug that interacts with COX & EPA is likely one of the reasons the FDA is politically and bureaucraticly dragging ass on an exclusivity decision. (Looking into Woodcock's Rhuematology connections)

Williams